http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 16:54:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05/26618142.html si-local-file:///var/storage/secattach/20260608/26618142.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05/26618142.html Mon, 08 Jun 2026 16:54:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05/26618142.html si-local-file:///var/storage/secattach/20260608/26618142.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05/26618142.html Mon, 08 Jun 2026 16:54:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Huennekens+R+Scott/26612181.html si-local-file:///var/storage/secattach/20260605/26612181.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Huennekens+R+Scott/26612181.html Fri, 05 Jun 2026 17:13:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Huennekens+R+Scott/26612181.html si-local-file:///var/storage/secattach/20260605/26612181.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Huennekens+R+Scott/26612181.html Fri, 05 Jun 2026 17:13:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Fischer+Frank+M/26612162.html si-local-file:///var/storage/secattach/20260605/26612162.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Fischer+Frank+M/26612162.html Fri, 05 Jun 2026 17:11:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Fischer+Frank+M/26612162.html si-local-file:///var/storage/secattach/20260605/26612162.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Fischer+Frank+M/26612162.html Fri, 05 Jun 2026 17:11:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Ryan+Renee/26612142.html si-local-file:///var/storage/secattach/20260605/26612142.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Ryan+Renee/26612142.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Ryan+Renee/26612142.html si-local-file:///var/storage/secattach/20260605/26612142.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Ryan+Renee/26612142.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Kumar+Rakhi/26612157.html si-local-file:///var/storage/secattach/20260605/26612157.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Kumar+Rakhi/26612157.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Kumar+Rakhi/26612157.html si-local-file:///var/storage/secattach/20260605/26612157.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Kumar+Rakhi/26612157.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Geiger+Uri/26612159.html si-local-file:///var/storage/secattach/20260605/26612159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Geiger+Uri/26612159.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Geiger+Uri/26612159.html si-local-file:///var/storage/secattach/20260605/26612159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Geiger+Uri/26612159.html Fri, 05 Jun 2026 17:10:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Andrade+Lisa/26612132.html si-local-file:///var/storage/secattach/20260605/26612132.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Andrade+Lisa/26612132.html Fri, 05 Jun 2026 17:09:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Andrade+Lisa/26612132.html si-local-file:///var/storage/secattach/20260605/26612132.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+05++Filed+by%3A+Andrade+Lisa/26612132.html Fri, 05 Jun 2026 17:09:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+03++Filed+by%3A+Becker+Joel/26605486.html si-local-file:///var/storage/secattach/20260604/26605486.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+03++Filed+by%3A+Becker+Joel/26605486.html Thu, 04 Jun 2026 16:03:00 -0400 NPCE O.00070719 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+03++Filed+by%3A+Becker+Joel/26605486.html si-local-file:///var/storage/secattach/20260604/26605486.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NeuroPace+Inc+++++++++++++For%3A+Jun+03++Filed+by%3A+Becker+Joel/26605486.html Thu, 04 Jun 2026 16:03:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Press+Releases/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html <p class="bwalignc"> <i>--</i><i>ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--</i> </p><p class="bwalignc"> <i>--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive http://www.streetinsider.com/Press+Releases/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html Fri, 29 May 2026 08:05:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Press+Releases/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html <p class="bwalignc"> <i>--</i><i>ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--</i> </p><p class="bwalignc"> <i>--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive http://www.streetinsider.com/Press+Releases/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html Fri, 29 May 2026 08:05:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Business+Wire/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html <p class="bwalignc"> <i>--</i><i>ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--</i> </p><p class="bwalignc"> <i>--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive http://www.streetinsider.com/Business+Wire/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html Fri, 29 May 2026 08:05:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Business+Wire/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html <p class="bwalignc"> <i>--</i><i>ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--</i> </p><p class="bwalignc"> <i>--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive http://www.streetinsider.com/Business+Wire/NeuroPace+to+Highlight+Expanding+Role+of+Responsive+Neuromodulation+at+the+2026+American+Society+for+Stereotactic+and+Functional+Neurosurgery+%28ASSFN%29+Meeting/26570933.html Fri, 29 May 2026 08:05:00 -0400 NPCE O.00070719 http://www.streetinsider.com/FDA/NeuroPace+receives+FDA+approval+for+AI-driven+epilepsy+care+tool/26570893.html <p>NeuroPace Inc. (NASDAQ: NPCE) announced FDA approval of ECoG Assistant, an artificial intelligence tool designed to support clinicians treating epilepsy patients. The Mountain View, California-based medical device company developed the tool using its database of intracranial EEG data.</p> <p>ECoG Assistant analyzes brain data captured through NeuroPace's RNS System to help physicians review electroencephalography records more efficiently. The AI model was trained on 124,450 epileptologist-labeled intracranial EEG long-episode records to identify patterns of clinical interest.</p> <p>The tool provides physicians with a trends report showing ECoGs of Interest over multiple months and includes a Circadian Pattern Chart to examine timing patterns. According to the http://www.streetinsider.com/FDA/NeuroPace+receives+FDA+approval+for+AI-driven+epilepsy+care+tool/26570893.html Fri, 29 May 2026 08:00:31 -0400 NPCE O.00070719 http://www.streetinsider.com/FDA/NeuroPace+receives+FDA+approval+for+AI-driven+epilepsy+care+tool/26570893.html <p>NeuroPace Inc. (NASDAQ: NPCE) announced FDA approval of ECoG Assistant, an artificial intelligence tool designed to support clinicians treating epilepsy patients. The Mountain View, California-based medical device company developed the tool using its database of intracranial EEG data.</p> <p>ECoG Assistant analyzes brain data captured through NeuroPace's RNS System to help physicians review electroencephalography records more efficiently. The AI model was trained on 124,450 epileptologist-labeled intracranial EEG long-episode records to identify patterns of clinical interest.</p> <p>The tool provides physicians with a trends report showing ECoGs of Interest over multiple months and includes a Circadian Pattern Chart to examine timing patterns. According to the http://www.streetinsider.com/FDA/NeuroPace+receives+FDA+approval+for+AI-driven+epilepsy+care+tool/26570893.html Fri, 29 May 2026 08:00:31 -0400 NPCE O.00070719 http://www.streetinsider.com/Press+Releases/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html <p class="bwalignc"> <i>-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. </p><p> <b>ECoG Assistant: Treatment Insights Simplified</b> </p><p> ECoG Assistant is the first http://www.streetinsider.com/Press+Releases/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html Fri, 29 May 2026 08:00:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Press+Releases/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html <p class="bwalignc"> <i>-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. </p><p> <b>ECoG Assistant: Treatment Insights Simplified</b> </p><p> ECoG Assistant is the first http://www.streetinsider.com/Press+Releases/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html Fri, 29 May 2026 08:00:00 -0400 NPCE O.00070719 http://www.streetinsider.com/Business+Wire/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html <p class="bwalignc"> <i>-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --</i> </p> <p> MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. </p><p> <b>ECoG Assistant: Treatment Insights Simplified</b> </p><p> ECoG Assistant is the first http://www.streetinsider.com/Business+Wire/NeuroPace+Announces+FDA+Approval+of+ECoG+Assistant%E2%84%A2%2C+Advancing+AI-Driven+Epilepsy+Care/26570860.html Fri, 29 May 2026 08:00:00 -0400 NPCE O.00070719